EMEA-001545-PIP01-13-M02
Key facts
| Invented name |
Dengvaxia
|
| Active substance |
|
| Therapeutic area |
Vaccines
|
| Decision number |
P/0065/2020
|
| PIP number |
EMEA-001545-PIP01-13-M02
|
| Pharmaceutical form(s) |
Powder and solvent for suspension for injection
|
| Condition(s) / indication(s) |
Prevention of dengue fever
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Sanofi pasteur
E-mail: contact-us@sanofi.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-001545-PIP01-13-M02
|
| Compliance opinion date |
29/05/2020
|
| Compliance outcome |
positive
|